PortfoliosLab logoPortfoliosLab logo
BTEK.L vs. BIOT.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BTEK.L vs. BIOT.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

BTEK.L is traded in GBP, while BIOT.L is traded in USD. To make them comparable, the BIOT.L values have been converted to GBP using the latest available exchange rates.

Returns By Period

In the year-to-date period, BTEK.L achieves a 14.42% return, which is significantly higher than BIOT.L's 7.49% return.


BTEK.L

1D
-0.14%
1M
8.62%
6M
12.42%
YTD
14.42%
1Y
48.32%
3Y*
16.28%
5Y*
6.26%
10Y*

BIOT.L

1D
0.00%
1M
6.51%
6M
6.57%
YTD
7.49%
1Y
31.98%
3Y*
8.83%
5Y*
3.12%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BTEK.L vs. BIOT.L - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BTEK.L
iShares Nasdaq US Biotechnology UCITS ETF
14.42%23.65%-0.20%0.30%-1.56%0.90%23.11%21.63%-6.79%
BIOT.L
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF
7.49%26.75%-3.66%-13.81%2.48%-2.69%24.52%8.73%0.06%

Correlation

The correlation between BTEK.L and BIOT.L is 0.82, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.82

Correlation (3Y)
Calculated over the trailing 3-year period

0.77

Correlation (5Y)
Calculated over the trailing 5-year period

0.78

Correlation (All Time)
Calculated using the full available price history since Jan 18, 2018

0.77

The correlation between BTEK.L and BIOT.L has been stable across timeframes, ranging from 0.77 to 0.82 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BTEK.L vs. BIOT.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTEK.L
BTEK.L Risk / Return Rank: 9191
Overall Rank
BTEK.L Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
BTEK.L Sortino Ratio Rank: 8989
Sortino Ratio Rank
BTEK.L Omega Ratio Rank: 8484
Omega Ratio Rank
BTEK.L Calmar Ratio Rank: 9696
Calmar Ratio Rank
BTEK.L Martin Ratio Rank: 9393
Martin Ratio Rank

BIOT.L
BIOT.L Risk / Return Rank: 6767
Overall Rank
BIOT.L Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
BIOT.L Sortino Ratio Rank: 6464
Sortino Ratio Rank
BIOT.L Omega Ratio Rank: 5555
Omega Ratio Rank
BIOT.L Calmar Ratio Rank: 8383
Calmar Ratio Rank
BIOT.L Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTEK.L vs. BIOT.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BTEK.LBIOT.LDifference
Sharpe ratioReturn per unit of total volatility

+0.88

Sortino ratioReturn per unit of downside risk

+1.09

Omega ratioGain probability vs. loss probability

1.40

1.27

+0.14

Calmar ratioReturn relative to maximum drawdown

6.98

3.15

+3.83

Martin ratioReturn relative to average drawdown

19.25

9.02

+10.24

BTEK.L vs. BIOT.L - Sharpe Ratio Comparison

The current BTEK.L Sharpe Ratio is 2.46, which is higher than the BIOT.L Sharpe Ratio of 1.58. The chart below compares the historical Sharpe Ratios of BTEK.L and BIOT.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BTEK.L vs. BIOT.L - Drawdown Comparison

The maximum BTEK.L drawdown since its inception was -36.03%, which is greater than BIOT.L's maximum drawdown of -30.68%. Use the drawdown chart below to compare losses from any high point for BTEK.L and BIOT.L.


Loading charts...

Drawdown Indicators


BTEK.LBIOT.LDifference

Max Drawdown

Largest peak-to-trough decline

-36.03%

-30.68%

-5.35%

Max Drawdown (1Y)

Largest decline over 1 year

-6.89%

-10.21%

+3.32%

Max Drawdown (3Y)

Largest decline over 3 years

-26.39%

-19.56%

-6.83%

Max Drawdown (5Y)

Largest decline over 5 years

-30.86%

-30.68%

-0.18%

Current Drawdown

Current decline from peak

-5.23%

-7.02%

+1.79%

Average Drawdown

Average peak-to-trough decline

-14.66%

-10.48%

-4.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.50%

3.57%

-1.07%

Volatility

BTEK.L vs. BIOT.L - Volatility Comparison

iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) have volatilities of 6.15% and 6.34%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BTEK.LBIOT.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.15%

6.34%

-0.19%

Volatility (6M)

Calculated over the trailing 6-month period

14.68%

15.32%

-0.64%

Volatility (1Y)

Calculated over the trailing 1-year period

19.59%

20.40%

-0.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

23.99%

17.99%

+6.00%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.97%

19.14%

+5.83%

BTEK.L vs. BIOT.L - Expense Ratio Comparison

BTEK.L has a 0.35% expense ratio, which is lower than BIOT.L's 0.49% expense ratio.


Dividends

BTEK.L vs. BIOT.L - Dividend Comparison

Neither BTEK.L nor BIOT.L has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


BTEK.L and BIOT.L have a correlation of 0.82, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BTEK.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BTEK.L is cheaper with a 0.35% expense ratio, compared with 0.49% for BIOT.L.

BTEK.L tracks NASDAQ Biotechnology TR USD, while BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return. They also come from different issuers: iShares and L&G. Their fees differ too: 0.35% for BTEK.L and 0.49% for BIOT.L.

Portfolio Optimizer

Find the right allocation for BTEK.L and BIOT.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer